Spire Wealth Management’s TG Therapeutics TGTX Stock Holding History

Spire Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22K	Hold	400	–	–	﹤0.01%	1415
2026 Q1	$13.3K	Hold	400	–	–	﹤0.01%	1541
2025 Q4	$11.9K	Hold	400	–	–	﹤0.01%	1651
2025 Q3	$14.4K	Hold	400	–	–	﹤0.01%	1628
2025 Q2	$14.4K	Sell	400 -22,750	-98%	-$847K	﹤0.01%	1610
2025 Q1	$913K	Buy	23,150 +22,750	+5,688%	+$765K	0.03%	423
2024 Q4	$12K	Buy	+400	New	+$11.5K	﹤0.01%	1793
2022 Q1	–	Sell	-80	Closed	-$2K	–	2853
2021 Q4	$2K	Sell	80 -657	-89%	-$17.1K	﹤0.01%	2806
2021 Q3	$25K	Hold	737	–	–	﹤0.01%	1770
2021 Q2	$29K	Buy	737 +298	+68%	+$11.7K	﹤0.01%	1726
2021 Q1	$36K	Buy	+439	New	+$21.1K	﹤0.01%	1893

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Spire Wealth Management's TGTX Position: Q2 2026 in Review

Spire Wealth Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 400 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1415.

Spire Wealth Management first reported a position in TGTX in Q1 2021 and has held it in 11 quarters since. The position peaked at $913K in Q1 2025. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Spire Wealth Management held 400 shares of TG Therapeutics worth $22K as of Q2 2026.
Spire Wealth Management left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up ﹤0.01% of Spire Wealth Management's portfolio in Q2 2026, its #1415 holding.
Spire Wealth Management first reported a position in TG Therapeutics in Q1 2021 and has held it in 11 quarters since.
Spire Wealth Management's TG Therapeutics position peaked at $913K in Q1 2025.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.